EFFICACY AND SAFETY PROFILE OF LURBINECTEDIN IN SECOND-LINE SCLC PATIENTS:

Results from a phase II single-agent trial

ASCO 2019

 

 

LURBINECTEDIN (PM01183) WITH DOXORUBICIN (DOX), AN ACTIVE TREATMENT AS SECOND-LINE THERAPY IN SMALL CELL LUNG CANCER (SCLC)

Foster M ASCO 2015

OVERALL SURVIVAL WITH LURBINECTEDIN PLUS DOXORUBICIN IN RELAPSED SCLC. RESULTS FROM AN EXPANSION COHORT OF A PHASE Ib TRIAL

IASLC. Toronto, 2018

ACTIVITY OF LURBINECTEDIN AS SINGLE AGENT AND IN COMBINATION IN PATIENTS WITH ADVANCED SMALL CELL LUNG CANCER (SCLC)

ESMO 2017

ACTIVITY AND SAFETY OF THE COMBINATION OF LURBINECTEDIN (PM1183) AND DOXORUBICIN IN RELAPSED SCLC. FINAL RESULTS OF A PHASE LB TRIAL

IASLC Yokohama – Japan 2017

EFFICACY AND SAFETY OF LURBINECTEDIN (PM1183, ZEPSYRE®) IN SMALL CELL LUNG CANCER (SCLC): RESULTS FROM A PHASE 2 STUDY

ASCO 2018

Alfonso Ortín
Communications Director

aortin@pharmamar.com

Miguel Martínez-Cava
Communication Manager

mmartinez-cava@pharmamar.com

Shareholders and Investors

Financial Information of the Company, stock information, official notices to the CNMV (Spanish Securities & Exchange Commission), product portfolio and other information.

Official Notices to the CNMV

Official notices to the CNMV including Price Sensitive Information.